Trial · NCT01677910
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 Weeks | Placebo | -0.623 | Standard Deviation 0.8275 | counts/day | |
| Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 Weeks | 250 mg Telotristat Etiprate | -1.433 | Standard Deviation 1.3652 | counts/day | |
| Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 Weeks | 500 mg Telotristat Etiprate | -1.455 | Standard Deviation 1.3098 | counts/day | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period | Placebo | 39 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period | 250 mg Telotristat Etiprate | 37 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period | 500 mg Telotristat Etiprate | 42 | Participants | ||
| Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA) Levels | Placebo | 11.350 | Standard Deviation 35.0346 | mg/24 hours | |
| Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA) Levels | 250 mg Telotristat Etiprate | -40.134 | Standard Deviation 84.7663 | mg/24 hours | |
| Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA) Levels | 500 mg Telotristat Etiprate | -57.519 | Standard Deviation 82.3273 | mg/24 hours | |
| Change From Baseline in the Number of Daily Cutaneous Flushing Episodes Averaged Across All Time-Points | Placebo | -0.164 | Standard Deviation 1.1572 | counts/day | |
| Change From Baseline in the Number of Daily Cutaneous Flushing Episodes Averaged Across All Time-Points | 250 mg Telotristat Etiprate | -0.296 | Standard Deviation 1.3097 | counts/day | |
| Change From Baseline in the Number of Daily Cutaneous Flushing Episodes Averaged Across All Time-Points | 500 mg Telotristat Etiprate | -0.525 | Standard Deviation 1.3413 | counts/day | |
| Change From Baseline in Abdominal Pain Averaged Across All Time-Points | Placebo | -0.226 | Standard Deviation 1.1601 | units on a scale | |
| Change From Baseline in Abdominal Pain Averaged Across All Time-Points | 250 mg Telotristat Etiprate | -0.489 | Standard Deviation 1.4423 | units on a scale | |
| Change From Baseline in Abdominal Pain Averaged Across All Time-Points | 500 mg Telotristat Etiprate | -0.333 | Standard Deviation 1.1784 | units on a scale | |
| Number of Participants With TEAEs in the Open-Label Extension Period | Telotristat Etiprate Open-Label Extension | 110 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01677910/results